Novo Nordisk is seeing brisk early demand for its new weight-loss pill as competition with ​U.S. rival Eli Lilly intensifies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results